Robert W. Baird Cuts Cellectis (NASDAQ:CLLS) Price Target to $21.00

Cellectis (NASDAQ:CLLS) had its target price decreased by equities researchers at Robert W. Baird from $28.00 to $21.00 in a research note issued on Tuesday, BenzingaRatingsTable reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price suggests a potential upside of 10.24% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Oppenheimer restated a “buy” rating and set a $35.00 price target on shares of Cellectis in a report on Thursday, May 7th. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Monday, April 27th. ValuEngine lowered Cellectis from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. BidaskClub lowered Cellectis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, TheStreet upgraded Cellectis from a “d+” rating to a “c-” rating in a research report on Monday, June 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $29.86.

Shares of Cellectis stock opened at $19.05 on Tuesday. The firm has a 50-day moving average of $18.13 and a 200-day moving average of $15.45. The stock has a market cap of $791.98 million, a PE ratio of -12.06 and a beta of 2.23. Cellectis has a 52-week low of $7.32 and a 52-week high of $21.97. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.64 and a current ratio of 7.71.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.06. Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. The firm had revenue of $51.91 million during the quarter, compared to analysts’ expectations of $21.07 million. Equities research analysts predict that Cellectis will post -1.47 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Envestnet Asset Management Inc. increased its holdings in Cellectis by 19.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 60,080 shares of the biotechnology company’s stock valued at $1,029,000 after buying an additional 9,852 shares during the last quarter. Atria Investments LLC purchased a new position in shares of Cellectis during the 4th quarter worth approximately $306,000. Citigroup Inc. increased its stake in shares of Cellectis by 136.3% during the 4th quarter. Citigroup Inc. now owns 1,531 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 883 shares in the last quarter. Advisor Group Inc. grew its stake in Cellectis by 19.6% in the 4th quarter. Advisor Group Inc. now owns 16,477 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 2,704 shares during the period. Finally, Credit Suisse AG grew its stake in Cellectis by 1.0% in the 4th quarter. Credit Suisse AG now owns 464,823 shares of the biotechnology company’s stock worth $7,958,000 after acquiring an additional 4,814 shares during the period. Institutional investors own 34.05% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Further Reading: What causes a recession?

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.